Join our daily newsletter At The Bell to receive exclusive market insights
- A recent study finds Recce Pharmaceutical’s (RCE) R327 candidate to demonstrate “outstanding efficacy” against flesh-eating bacteria
- The study found RCE’s synthetic anti-infective reduced the “flesh-eating” bacterial count of necrotizing fasciitis
- Data from the study is also evidence of the candidate’s potential against diabetic wounds and infected ulcers
- Recce’s Chief Scientific Officer Michele Diliza said the candidate could significantly change the treatment paradigm and save lives
- Recce Pharmaceuticals shares were up 6.59 per cent to trade at 97 cents
A recent study has found Recce Pharmaceutical’s (RCE) R327 candidate to demonstrate “outstanding efficacy” against flesh-eating bacteria.
An independent study was conducted to test RCE’s synthetic anti-infective R327 against two strains of necrotizing fasciitis — a life-threatening bacterial infection with a mortality rate of up to 80 per cent.
The study found R327 reduced deadly ‘flesh-eating’ bacterial count Below Limit of Quantification (BLOQ) within 24 hours and demonstrated efficacy 30 minutes into testing.
Broadly, RCE said the data demonstrate R327’s potential against bacterial infections that thrive in nil to low oxygen environments such as diabetic wounds and ulcers infections.
Recce Pharmaceuticals Chief Scientific Officer Michele Diliza said necrotizing fasciitis can lead to serious complications and is challenging for physicians and families alike.
“A broad-spectrum anti-infective with rapid efficacy has the potential to significantly change the treatment paradigm and save lives,” he said.
“We have been thoroughly impressed with the efficacy that R327 has demonstrated thus far, as it reinforces our belief in the potential of this compound against such aggressive, life-threatening bacteria.”
Recce Pharmaceuticals shares were up 6.59 per cent to trade at 97 cents at 2:35 pm AEST.
